Contra-indicated in patients with known or suspected gastrointestinal obstruction, patients at increased risk of recurrent gastrointestinal obstruction, and patients concomitantly using strong CYP3A4 inhibitors.
- TRADE NAME: Movantik (AstraZeneca)
- INDICATIONS: Opioid-induced constipation
- CLASS: Opioid receptor antagonist
- HALF-LIFE: 6–11 hours
- FDA APPROVAL DATE: 09/16/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Diltiazem, Erythromycin, Grapefruit Juice, Verapamil, Viloxazine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
